Modelling HIV and MTB co-infection including combined treatment strategies.

A new host-pathogen model is described that simulates HIV-MTB co-infection and treatment, with the objective of testing treatment strategies. The model includes CD4+ and CD8+ T cells, resting and activated macrophages, HIV and Mycobacterium tuberculosis (MTB). For TB presentation at various stages o...

Full description

Bibliographic Details
Main Authors: Santosh Ramkissoon, Henry G Mwambi, Alan P Matthews
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3509125?pdf=render
id doaj-51656e3c43e549beb5b97f7528b706e6
record_format Article
spelling doaj-51656e3c43e549beb5b97f7528b706e62020-11-25T01:29:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01711e4949210.1371/journal.pone.0049492Modelling HIV and MTB co-infection including combined treatment strategies.Santosh RamkissoonHenry G MwambiAlan P MatthewsA new host-pathogen model is described that simulates HIV-MTB co-infection and treatment, with the objective of testing treatment strategies. The model includes CD4+ and CD8+ T cells, resting and activated macrophages, HIV and Mycobacterium tuberculosis (MTB). For TB presentation at various stages of HIV disease in a co-infected individual, combined treatment strategies were tested with different relative timings of treatment for each infection. The stages were early HIV disease, late HIV disease and AIDS. The main strategies were TB treatment followed by anti-retroviral therapy (ART) after delays of 15 days, 2 months and 6 months. ART followed by TB treatment was an additional strategy that was tested. Treatment was simulated with and without drug interaction. Simulation results were that TB treatment first followed by ART after a stage-dependent delay has the best outcome. During early HIV disease a 6 month delay is acceptable. During late HIV disease, a 2 month delay is best. During AIDS it is better to start ART after 15 days. However, drug interaction works against the benefits of early ART. These results agree with expert reviews and clinical trials.http://europepmc.org/articles/PMC3509125?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Santosh Ramkissoon
Henry G Mwambi
Alan P Matthews
spellingShingle Santosh Ramkissoon
Henry G Mwambi
Alan P Matthews
Modelling HIV and MTB co-infection including combined treatment strategies.
PLoS ONE
author_facet Santosh Ramkissoon
Henry G Mwambi
Alan P Matthews
author_sort Santosh Ramkissoon
title Modelling HIV and MTB co-infection including combined treatment strategies.
title_short Modelling HIV and MTB co-infection including combined treatment strategies.
title_full Modelling HIV and MTB co-infection including combined treatment strategies.
title_fullStr Modelling HIV and MTB co-infection including combined treatment strategies.
title_full_unstemmed Modelling HIV and MTB co-infection including combined treatment strategies.
title_sort modelling hiv and mtb co-infection including combined treatment strategies.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description A new host-pathogen model is described that simulates HIV-MTB co-infection and treatment, with the objective of testing treatment strategies. The model includes CD4+ and CD8+ T cells, resting and activated macrophages, HIV and Mycobacterium tuberculosis (MTB). For TB presentation at various stages of HIV disease in a co-infected individual, combined treatment strategies were tested with different relative timings of treatment for each infection. The stages were early HIV disease, late HIV disease and AIDS. The main strategies were TB treatment followed by anti-retroviral therapy (ART) after delays of 15 days, 2 months and 6 months. ART followed by TB treatment was an additional strategy that was tested. Treatment was simulated with and without drug interaction. Simulation results were that TB treatment first followed by ART after a stage-dependent delay has the best outcome. During early HIV disease a 6 month delay is acceptable. During late HIV disease, a 2 month delay is best. During AIDS it is better to start ART after 15 days. However, drug interaction works against the benefits of early ART. These results agree with expert reviews and clinical trials.
url http://europepmc.org/articles/PMC3509125?pdf=render
work_keys_str_mv AT santoshramkissoon modellinghivandmtbcoinfectionincludingcombinedtreatmentstrategies
AT henrygmwambi modellinghivandmtbcoinfectionincludingcombinedtreatmentstrategies
AT alanpmatthews modellinghivandmtbcoinfectionincludingcombinedtreatmentstrategies
_version_ 1725097796638343168